Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells

BACKGROUND: Canagliflozin (CANA) administration increases the risk of lower limb amputation in the clinic. The present study aimed to investigate whether and how CANA interferes with the intracellular physiological processes of bone marrow derived mesenchymal stem cells (BM-MSCs) and its contributio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yinuo, Nan, Jinliang, Shen, Jian, Lv, Xinhuang, Chen, Xiao, Lu, Xingmei, Zhang, Chi, Xiang, Pingping, Wang, Zhiting, Li, Zhengzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992997/
https://www.ncbi.nlm.nih.gov/pubmed/31981975
http://dx.doi.org/10.1016/j.ebiom.2020.102637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992997/
https://www.ncbi.nlm.nih.gov/pubmed/31981975
http://dx.doi.org/10.1016/j.ebiom.2020.102637

Ejemplares similares